Cellartis hiPS beta cells have been differentiated from our ChiPSC12 and ChiPSC22 lines of control human induced pluripotent stem (hiPS) cells, dissociated into a single-cell suspension, and frozen in vials. Each kit contains beta cells, coating substrate, basal media, and a supplement.
Cellartis hiPS cell-derived beta cell kits contain beta cells generated in vitro using a standardized protocol that mimics embryonic development. These cells secrete high amounts of insulin and C-peptide, and they show substantial protein expression of insulin/C-peptide, MAFA, NKX6-1, PDX1, and UCN3. We offer two complete kits, each containing cells that originate from healthy human donors, including one with a diabetes-susceptible HLA type (HLA-A*02:01). The kits are ideal for investigating beta cell function, diabetes/disease modeling, and compound screening for insulin secretion and regulation.
Overview
- Beta cells from ChiPSC12 and ChiPSC22 originate from healthy human donors
- Beta cells from ChiPSC22 originate from a donor with a diabetes-susceptible HLA type, HLA-A*02:01 (Marron et al. 2002)
- Beta cells from ChiPSC22 can be used alone or in combination with beta cells from ChiPSC12, which have an alternate HLA type
- Cells show protein expression of insulin/C-peptide, MAFA, NKX6-1, PDX1, and UCN3
- Cells demonstrate insulin and C-peptide secretion
- Cells were derived with a protocol that mimics embryonic development
- Cells provide reproducible and biologically relevant data
Applications
- Disease modeling for diabetes
- Compound screening for insulin secretion and regulation
- Beta-cell functionality
- GSIS (glucose-stimulated insulin secretion) analysis
- Incretin response studies
- Autoimmune beta-cell destruction
- Pancreatitis and beta-cell function
- Transdifferentiation



